Abstract
Medulloblastoma comprises the most common malignant pediatric brain tumor. Current treatment protocols are solely based on clinically defined risk-groups. Identification of novel tumor-derived markers may improve the risk assessment of medulloblastoma patients. Thus, array-CGH or FISH were carried out to determine tumor-specific genomic imbalances associated with overall survival (OS) in 340 medulloblastoma patients. Detection of MYC-/MYCN amplification, Trisomy 6, 17p-loss or 17q-gain was linked to high molecular risk. In contrast, medulloblastomas with Monosomy 6 and balanced copy-number status of 6q, 17p, 17q, MYC, and MYCN were associated with low molecular risk. This set of genomic markers was significantly correlated with OS (p<0.001).
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
